» Articles » PMID: 24465399

Global Dormancy of Metastases Due to Systemic Inhibition of Angiogenesis

Overview
Journal PLoS One
Date 2014 Jan 28
PMID 24465399
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Autopsy studies of adults dying of non-cancer causes have shown that virtually all of us possess occult, cancerous lesions. This suggests that, for most individuals, cancer will become dormant and not progress, while only in some will it become symptomatic disease. Meanwhile, it was recently shown in animal models that a tumor can produce both stimulators and inhibitors of its own blood supply. To explain the autopsy findings in light of the preclinical research data, we propose a mathematical model of cancer development at the organism scale describing a growing population of metastases, which, together with the primary tumor, can exert a progressively greater level of systemic angiogenesis-inhibitory influence that eventually overcomes local angiogenesis stimulation to suppress the growth of all lesions. As a departure from modeling efforts to date, we look not just at signaling from and effects on the primary tumor, but integrate over this increasingly negative global signaling from all sources to track the development of total tumor burden. This in silico study of the dynamics of the tumor/metastasis system identifies ranges of parameter values where mutual angio-inhibitory interactions within a population of tumor lesions could yield global dormancy, i.e., an organism-level homeostatic steady state in total tumor burden. Given that mortality arises most often from metastatic disease rather than growth of the primary per se, this finding may have important therapeutic implications.

Citing Articles

Hypothesis: Cancer Hormesis and Its Potential for Cancer Therapeutics.

Bordonaro M, Lazarova D Life (Basel). 2024; 14(3).

PMID: 38541725 PMC: 10972146. DOI: 10.3390/life14030401.


Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer.

Stalin J, Coquoz O, Jeitziner Marcone R, Jemelin S, Desboeufs N, Delorenzi M Biomedicines. 2023; 11(12).

PMID: 38137406 PMC: 10740863. DOI: 10.3390/biomedicines11123185.


Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer.

Bilous M, Serdjebi C, Boyer A, Tomasini P, Pouypoudat C, Barbolosi D Sci Rep. 2019; 9(1):13018.

PMID: 31506498 PMC: 6736889. DOI: 10.1038/s41598-019-49407-3.


Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer.

Jahanban-Esfahlan R, Seidi K, Manjili M, Jahanban-Esfahlan A, Javaheri T, Zare P Cancers (Basel). 2019; 11(8).

PMID: 31430951 PMC: 6721805. DOI: 10.3390/cancers11081207.


Obesity paradox in cancer: Is bigger really better?.

Ujvari B, Jacqueline C, Misse D, Amar V, Fitzpatrick J, Jennings G Evol Appl. 2019; 12(6):1092-1095.

PMID: 31293625 PMC: 6597865. DOI: 10.1111/eva.12790.


References
1.
Almog N . Molecular mechanisms underlying tumor dormancy. Cancer Lett. 2010; 294(2):139-46. DOI: 10.1016/j.canlet.2010.03.004. View

2.
OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View

3.
Folkman J . Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007; 6(4):273-86. DOI: 10.1038/nrd2115. View

4.
Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

5.
Gunduz N, Fisher B, Saffer E . Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979; 39(10):3861-5. View